

Miguel Martin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2029886/publications.pdf>

Version: 2024-02-01

437
papers

29,299
citations

5569

82
h-index

5986

160
g-index

447
all docs

447
docs citations

447
times ranked

25140
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant Trastuzumab in HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2011, 365, 1273-1283.	13.9	2,254
2	Palbociclib and Letrozole in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1925-1936.	13.9	1,943
3	Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation. <i>New England Journal of Medicine</i> , 2018, 379, 753-763.	13.9	1,472
4	Adjuvant Docetaxel for Node-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2005, 352, 2302-2313.	13.9	892
5	Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. <i>Journal of Clinical Oncology</i> , 2018, 36, 2465-2472.	0.8	704
6	Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4594-4600.	0.8	553
7	A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1873.	3.8	531
8	Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 514-524.	13.9	482
9	Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2~, Node-Positive, High-Risk, Early Breast Cancer (monarchE). <i>Journal of Clinical Oncology</i> , 2020, 38, 3987-3998.	0.8	478
10	Prognostic Significance of Progesterone Receptor-Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 203-209.	0.8	464
11	Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 1168-1176.	0.8	461
12	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1688-1700.	5.1	451
13	The Global Breast Cancer Burden: Variations in Epidemiology and Survival. <i>Clinical Breast Cancer</i> , 2005, 6, 391-401.	1.1	445
14	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 367-377.	5.1	444
15	Missing data imputation using statistical and machine learning methods in a real breast cancer problem. <i>Artificial Intelligence in Medicine</i> , 2010, 50, 105-115.	3.8	381
16	21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 2336-2347.	13.9	363
17	Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 968-975.	0.8	358
18	MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 5.	2.3	352

#	ARTICLE	IF	CITATIONS
19	Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 115-126.	5.1	333
20	Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 1.	2.3	331
21	Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 141-148.	0.8	327
22	Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. <i>Nature Communications</i> , 2018, 9, 2897.	5.8	293
23	B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer. <i>Cell</i> , 2019, 179, 1191-1206.e21.	13.5	291
24	Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 3399-3406.	0.8	273
25	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37-298 women with early breast cancer in 26 randomised trials. <i>Lancet</i> , The, 2019, 393, 1440-1452.	6.3	260
26	PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers. <i>BMC Medical Genomics</i> , 2012, 5, 44.	0.7	250
27	Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. <i>Annals of Oncology</i> , 2021, 32, 1571-1581.	0.6	225
28	Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens. <i>Journal of Clinical Oncology</i> , 2011, 29, 149-156.	0.8	222
29	Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt337-djt337.	3.0	218
30	Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 1031-1039.	0.8	216
31	Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer. <i>Oncologist</i> , 2011, 16, 1092-1100.	1.9	215
32	Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2008, 100, 805-814.	3.0	208
33	Docetaxel-related side effects and their management. <i>European Journal of Oncology Nursing</i> , 2009, 13, 49-59.	0.9	200
34	Cancer Therapy-Induced Cardiac Toxicity in Early Breast Cancer. <i>Circulation</i> , 2012, 126, 2749-2763.	1.6	198
35	Alteration of Topoisomerase II-Alpha Gene in Human Breast Cancer: Association With Responsiveness to Anthracycline-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2011, 29, 859-867.	0.8	192
36	Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. <i>Lancet Oncology</i> , The, 2013, 14, 72-80.	5.1	192

#	ARTICLE	IF	CITATIONS
37	Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 121-131.	1.1	191
38	Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 5351-5361.	3.2	185
39	Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. <i>Lancet Oncology</i> , The, 2007, 8, 219-225.	5.1	181
40	Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. <i>Annals of Oncology</i> , 2006, 17, 1205-1212.	0.6	171
41	Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. <i>Lancet Oncology</i> , The, 2014, 15, 156-163.	5.1	171
42	Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2010, 363, 2200-2210.	13.9	169
43	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2021, 22, 212-222.	5.1	169
44	Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. <i>Annals of Oncology</i> , 2016, 27, 379-390.	0.6	165
45	Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 60-72.	5.1	161
46	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancerâ€”The Penelope-B Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1518-1530.	0.8	153
47	Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2â€”Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2206-2216.	0.8	152
48	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. <i>Lancet Oncology</i> , The, 2022, 23, 149-160.	5.1	148
49	Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2â€”Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. <i>Journal of Clinical Oncology</i> , 2015, 33, 1574-1583.	0.8	146
50	Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 447-455.	1.0	146
51	Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) in breast cancer: a randomised controlled trial. <i>Lancet Oncology</i> , 2003, 14, 833-842.	0.6	145
52	Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression. <i>Oncologist</i> , 2015, 20, 474-482.	1.9	145
53	Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. <i>Annals of Oncology</i> , 2021, 32, 1015-1024.	0.6	144
54	Spanish Mediterranean diet and other dietary patterns and breast cancer risk: caseâ€”control EpiGEICAM study. <i>British Journal of Cancer</i> , 2014, 111, 1454-1462.	2.9	141

#	ARTICLE	IF	CITATIONS
55	Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. <i>Clinical Breast Cancer</i> , 2021, 21, 80-91.e7.	1.1	140
56	Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2â€“Normal, Node-Positive Breast Cancer: BCIRG-005 Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 3877-3884.	0.8	135
57	A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. <i>European Journal of Cancer</i> , 2013, 49, 3763-3772.	1.3	133
58	Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2âˆ“ breast cancer patients: results from the GEICAM 9906 trial. <i>Breast Cancer Research</i> , 2014, 16, R38.	2.2	133
59	A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2âˆ“ advanced breast cancer (BELLE-4). <i>Annals of Oncology</i> , 2017, 28, 313-320.	0.6	133
60	Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 88-96.	5.1	128
61	Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2âˆ“ Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 566-580.	3.2	125
62	Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations. <i>Oncologist</i> , 2009, 14, 1-11.	1.9	124
63	Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid. <i>Clinical Cancer Research</i> , 2012, 18, 4841-4849.	3.2	124
64	Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-NaÃ“ve Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 110-121.	3.2	120
65	Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2âˆ“Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3626-3633.	0.8	118
66	Multicenter Randomized Trial Comparing Sequential With Concomitant Administration of Doxorubicin and Docetaxel As First-Line Treatment of Metastatic Breast Cancer: A Spanish Breast Cancer Research Group (GEICAM-9903) Phase III Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 2587-2593.	0.8	115
67	Neoadjuvant treatments for triple-negative breast cancer (TNBC). <i>Annals of Oncology</i> , 2012, 23, vi35-vi39.	0.6	115
68	Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 141-148.	0.8	113
69	<i>HER2</i> Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials. <i>Journal of Clinical Oncology</i> , 2016, 34, 3518-3528.	0.8	113
70	Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 1045-1052.	0.8	108
71	Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. <i>Clinical Cancer Research</i> , 2017, 23, 649-657.	3.2	108
72	Quality of life with talazoparib versus physicianâ€™s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. <i>Annals of Oncology</i> , 2018, 29, 1939-1947.	0.6	107

#	ARTICLE	IF	CITATIONS
73	Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. <i>Annals of Oncology</i> , 2012, 23, 625-631.	0.6	106
74	Analysis of FcÎ³ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2012, 18, 3478-3486.	3.2	106
75	Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. <i>Annals of Oncology</i> , 2018, 29, 888-894.	0.6	104
76	Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1073-1079.	0.8	102
77	Predicting response and survival in chemotherapy-treated triple-negative breast cancer. <i>British Journal of Cancer</i> , 2014, 111, 1532-1541.	2.9	100
78	Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. <i>Lancet Oncology</i> , The, 2018, 19, 812-824.	5.1	98
79	PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 457-466.	1.1	96
80	A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants atDPYDand a putative role forENOSF1rather thanTYMS. <i>Gut</i> , 2015, 64, 111-120.	6.1	93
81	Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. <i>European Journal of Cancer</i> , 2016, 53, 75-83.	1.3	92
82	Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. <i>British Journal of Cancer</i> , 2018, 118, 1056-1061.	2.9	89
83	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2022, 40, 282-293.	0.8	88
84	Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). <i>Journal of Clinical Oncology</i> , 2020, 38, 203-213.	0.8	87
85	Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. <i>Clinical Cancer Research</i> , 2018, 24, 1845-1852.	3.2	84
86	Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. <i>Clinical Cancer Research</i> , 2018, 24, 5820-5829.	3.2	82
87	Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. <i>Breast Cancer Research</i> , 2013, 15, R105.	2.2	80
88	Strategies to design clinical studies to identify predictive biomarkers in cancer research. <i>Cancer Treatment Reviews</i> , 2017, 53, 79-97.	3.4	80
89	Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. , 2022, 10, e003776.		79
90	Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 149-157.	1.1	77

#	ARTICLE	IF	CITATIONS
91	A Polymorphism in the <i>Cytidine Deaminase</i> Promoter Predicts Severe Capecitabine-Induced Hand-Foot Syndrome. <i>Clinical Cancer Research</i> , 2011, 17, 2006-2013.	3.2	75
92	Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. <i>Annals of Oncology</i> , 2018, 29, 669-680.	0.6	74
93	Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. <i>Lancet Oncology</i> , The, 2011, 12, 369-376.	5.1	73
94	Supervised physical exercise improves VO ₂ max, quality of life, and health in early stage breast cancer patients: a randomized controlled trial. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 371-382.	1.1	73
95	PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2- advanced breast cancer (ABC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 507-507.	0.8	72
96	Epirubicin cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. <i>Annals of Oncology</i> , 2004, 15, 79-87.	0.6	69
97	Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 169-176.	1.1	69
98	Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial PEARL. <i>Annals of Oncology</i> , 2021, 32, 488-499.	0.6	69
99	Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE. <i>Cancer</i> , 2019, 125, 3974-3984.	2.0	67
100	Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 127-136.	1.1	66
101	Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET). <i>Annals of Oncology</i> , 2016, 27, 1719-1725.	0.6	64
102	INCIDENCE-BASED COST-OF-ILLNESS MODEL FOR METASTATIC BREAST CANCER IN THE UNITED STATES. <i>International Journal of Technology Assessment in Health Care</i> , 2012, 28, 12-21.	0.2	62
103	Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 377-386.	1.1	61
104	Assessment of Topoisomerase II Status in Breast Cancer by Quantitative PCR, Gene Expression Microarrays, Immunohistochemistry, and Fluorescence in Situ Hybridization. <i>American Journal of Pathology</i> , 2011, 178, 1453-1460.	1.9	59
105	Differences in the Therapeutic Approach to Colorectal Cancer in Young and Elderly Patients. <i>Oncologist</i> , 2012, 17, 1277-1285.	1.9	59
106	PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. <i>Clinical Cancer Research</i> , 2015, 21, 2065-2074.	3.2	59
107	IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. <i>Future Oncology</i> , 2019, 15, 1951-1961.	1.1	58
108	Influence of Timing of Initiation of Adjuvant Chemotherapy Over Survival in Breast Cancer: A Negative Outcome Study by the Spanish Breast Cancer Research Group (GEICAM). <i>Breast Cancer Research and Treatment</i> , 2007, 101, 215-223.	1.1	57

#	ARTICLE	IF	CITATIONS
109	Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3788-3795.	0.8	56
110	Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study. <i>PLoS ONE</i> , 2015, 10, e0126096.	1.1	56
111	Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 507-507.	0.8	55
112	Estrogen Receptor Expression and Efficacy of Docetaxel-Containing Adjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: Results From a Pooled Analysis. <i>Journal of Clinical Oncology</i> , 2008, 26, 2636-2643.	0.8	54
113	Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 501-501.	0.8	54
114	A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 1139-1148.	1.1	52
115	Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 2593-2599.	0.8	52
116	Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer. <i>Oncologist</i> , 2012, 17, 469-475.	1.9	48
117	Running away from side effects: physical exercise as a complementary intervention for breast cancer patients. <i>Clinical and Translational Oncology</i> , 2015, 17, 180-196.	1.2	47
118	Trastuzumab Associated with Successive Cytotoxic Therapies Beyond Disease Progression in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2005, 6, 325-329.	1.1	46
119	Reclassification of the members of the genus <i>Tetrathiodacter</i> Ghosh et al. 2005 to the genus <i>Advenella</i> Coenye et al. 2005. <i>International Journal of Systematic and Evolutionary Microbiology</i> , 2009, 59, 1914-1918.	0.8	44
120	NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptorâ€“positive (HR+), human epidermal growth factor receptor 2â€“negative (HER2â€“) early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS597-TPS597.	0.8	44
121	Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy. <i>Breast Cancer Research</i> , 2001, 3, 183-91.	2.2	43
122	Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. <i>Annals of Oncology</i> , 2003, 14, 1246-1252.	0.6	43
123	Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement. <i>Oncologist</i> , 2019, 24, 603-611.	1.9	43
124	Exercise and cancer: a position statement from the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2020, 22, 1710-1729.	1.2	43
125	Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. <i>BMC Cancer</i> , 2019, 19, 517.	1.1	42
126	Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 903-913.	1.1	41

#	ARTICLE	IF	CITATIONS
127	Circulating Tumor Cells Following First Chemotherapy Cycle: An Early and Strong Predictor of Outcome in Patients With Metastatic Breast Cancer. <i>Oncologist</i> , 2013, 18, 917-923.	1.9	41
128	Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 96-106.	2.0	41
129	Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. <i>Npj Breast Cancer</i> , 2018, 4, 41.	2.3	41
130	Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 591-600.	1.1	38
131	Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 81-89.	1.1	38
132	Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. <i>JCO Global Oncology</i> , 2021, 7, 162-172.	0.8	38
133	BCIRG 001 Molecular Analysis: Prognostic Factors in Node-Positive Breast Cancer Patients Receiving Adjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2010, 16, 3988-3997.	3.2	37
134	Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer. <i>Current Medical Research and Opinion</i> , 2015, 31, 1129-1137.	0.9	37
135	Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. <i>Supportive Care in Cancer</i> , 2012, 20, 2661-2668.	1.0	36
136	Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series. <i>BMC Genomics</i> , 2019, 20, 452.	1.2	36
137	Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA671-LBA671.	0.8	36
138	Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3014-3014.	0.8	36
139	REMOVED: Docetaxel-related side effects and their management. <i>European Journal of Oncology Nursing</i> , 2008, 12, 253-268.	0.9	34
140	SEOM Clinical Guideline for bone metastases from solid tumours (2016). <i>Clinical and Translational Oncology</i> , 2016, 18, 1243-1253.	1.2	34
141	Physical activity and breast cancer risk by pathological subtype. <i>Gynecologic Oncology</i> , 2017, 144, 577-585.	0.6	34
142	Molecular biology of breast cancer. <i>Clinical and Translational Oncology</i> , 2006, 8, 7-14.	1.2	33
143	A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothed or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012â€™12 (EDALINE) study. <i>Investigational New Drugs</i> , 2019, 37, 98-108.	1.2	33
144	Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE).. <i>Journal of Clinical Oncology</i> , 2016, 34, 500-500.	0.8	32

#	ARTICLE	IF	CITATIONS
145	Bevacizumab Treatment for Advanced Breast Cancer. <i>Oncologist</i> , 2011, 16, 1684-1697.	1.9	31
146	Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups. <i>Npj Breast Cancer</i> , 2021, 7, 80.	2.3	31
147	Triple negative breast cancer: Proposals for a pragmatic definition and implications for patient management and trial design. <i>Breast</i> , 2012, 21, 20-26.	0.9	30
148	Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. <i>Breast Cancer Research</i> , 2015, 17, 56.	2.2	30
149	Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. <i>Annals of Oncology</i> , 2016, 27, 1249-1256.	0.6	29
150	Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial. <i>Annals of Surgical Oncology</i> , 2017, 24, 398-406.	0.7	29
151	Oncological care organisation during COVID-19 outbreak. <i>ESMO Open</i> , 2020, 5, e000853.	2.0	29
152	Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifestuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 364-372.	3.2	29
153	A Randomized, Double-Blind, Phase II Study of Two Doses of Pemetrexed as First-Line Chemotherapy for Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 3652-3659.	3.2	28
154	TRIO-012: A Multicenter, Multinational, Randomized, Double-Blind Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally Recurrent or Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2009, 9, 258-261.	1.1	28
155	Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study. <i>Annals of Oncology</i> , 2011, 22, 2591-2596.	0.6	28
156	A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. <i>Clinical Cancer Research</i> , 2017, 23, 3035-3044.	3.2	28
157	Outcomes of COVID-19 in Patients With Lung Cancer Treated in a Tertiary Hospital in Madrid. <i>Frontiers in Oncology</i> , 2020, 10, 1777.	1.3	28
158	Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2-Advanced Breast Cancer. <i>Oncologist</i> , 2020, 25, e1346-e1354.	1.9	28
159	Recent advances in systemic therapy. Advances in adjuvant systemic chemotherapy of early breast cancer. <i>Breast Cancer Research</i> , 2009, 11, 204.	2.2	27
160	Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 507-515.	1.1	27
161	Proposal for the creation of a national strategy for precision medicine in cancer: a position statement of SEOM, SEAP, and SEFH. <i>Clinical and Translational Oncology</i> , 2018, 20, 443-447.	1.2	27
162	Neratinib (HKI-272) in the treatment of breast cancer. <i>Future Oncology</i> , 2012, 8, 671-681.	1.1	26

#	ARTICLE	IF	CITATIONS
163	Levels and predictors of persistent organic pollutants in an adult population from four Spanish regions. <i>Science of the Total Environment</i> , 2015, 538, 152-161.	3.9	26
164	Assessment of <i>ERBB2</i> / <i>HER2</i> Status in <i>HER2</i> -Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines. <i>JAMA Oncology</i> , 2019, 5, 366.	3.4	26
165	Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer. <i>Cancer</i> , 2012, 118, 241-247.	2.0	25
166	Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 4072-4080.	3.2	25
167	Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study. <i>Breast</i> , 2020, 54, 148-154.	0.9	25
168	BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). <i>Journal of Clinical Oncology</i> , 2007, 25, LBA1008-LBA1008.	0.8	25
169	Phase II Study of Pegylated Liposomal Doxorubicin plus Vinorelbine in Breast Cancer with Previous Anthracycline Exposure. <i>Clinical Breast Cancer</i> , 2004, 5, 353-357.	1.1	24
170	Denosumab for the treatment of bone metastases in advanced breast cancer. <i>Breast</i> , 2013, 22, 585-592.	0.9	24
171	A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. <i>GEICAM/2010-04 study. Oncotarget</i> , 2017, 8, 73144-73153.	0.8	24
172	Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz085.	1.4	24
173	A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting) Tj ETQq1 1 0.784314 rgBT /Ove HER2-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 587-587.	0.8	24
174	Paclitaxel plus vinorelbine: An active regimen in metastatic breast cancer patients with prior anthracycline exposure. <i>Annals of Oncology</i> , 2000, 11, 85-90.	0.6	23
175	Exome array analysis identifies ETV6 as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 249-256.	1.1	23
176	Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 627-634.	1.1	23
177	Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study. <i>Scientific Reports</i> , 2019, 9, 3904.	1.6	23
178	nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, 181-190.e2.	1.1	23
179	Capecitabine plus docetaxel combination therapy. <i>Cancer</i> , 2005, 103, 2455-2465.	2.0	22
180	Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?. <i>Clinical and Translational Oncology</i> , 2012, 14, 163-168.	1.2	22

#	ARTICLE	IF	CITATIONS
181	Neratinib for the treatment of HER2-positive early stage breast cancer. Expert Review of Anticancer Therapy, 2017, 17, 669-679.	1.1	22
182	nab-Paclitaxel dose and schedule in breast cancer. Breast Cancer Research, 2015, 17, 81.	2.2	21
183	Outcomes of single versus double hormone receptor- ⁺ positive breast cancer. A GEICAM/9906 sub-study. European Journal of Cancer, 2018, 94, 199-205.	1.3	21
184	Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2. Clinical Breast Cancer, 2020, 20, e173-e180.	1.1	21
185	Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population. Breast Cancer Research and Treatment, 2021, 189, 689-699.	1.1	21
186	Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2 ⁻) advanced breast cancer (ABC): Results from MONALEESA-3.. Journal of Clinical Oncology, 2018, 36, 1000-1000.	0.8	21
187	Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy. JAMA Oncology, 2022, 8, 1190.	3.4	21
188	Characterization of uncertainty in the classification of multivariate assays: application to PAM50 centroid-based genomic predictors for breast cancer treatment plans. Journal of Clinical Bioinformatics, 2011, 1, 37.	1.2	20
189	Health-Related Quality of Life With Adjuvant Docetaxel- and Trastuzumab-Based Regimens in Patients with Node-Positive and High-Risk Node-Negative, HER2-Positive Early Breast Cancer: Results from the BCIRG 006 Study. Oncologist, 2013, 18, 812-818.	1.9	20
190	The evolving landscape of protein kinases in breast cancer: Clinical implications. Cancer Treatment Reviews, 2013, 39, 68-76.	3.4	20
191	Standard Versus Continuous Administration of Capecitabine in Metastatic Breast Cancer (GEICAM/2009-05): A Randomized, Noninferiority Phase II Trial With a Pharmacogenetic Analysis. Oncologist, 2015, 20, 111-112.	1.9	20
192	Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2 ⁻) early breast cancer (EBC): results from the GEICAM/2006-10 study. Breast Cancer Research and Treatment, 2019, 177, 115-125.	1.1	20
193	Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient's management and therapy selection. Clinical and Translational Oncology, 2014, 16, 386-394.	1.2	19
194	Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial. Annals of Oncology, 2019, 30, 567-574.	0.6	19
195	Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. European Journal of Cancer, 2021, 151, 49-62.	1.3	19
196	Abstract GS5-01: Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis. Cancer Research, 2020, 80, GS5-01-GS5-01.	0.4	19
197	Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer. Breast, 2007, 16, 127-131.	0.9	18
198	Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer. British Journal of Cancer, 2010, 103, 1524-1528.	2.9	18

#	ARTICLE	IF	CITATIONS
199	The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients. <i>European Journal of Cancer</i> , 2008, 44, 353-365.	1.3	17
200	Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor- positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBC51) and CALGB 40503 (Alliance) trials. <i>European Journal of Cancer</i> , 2019, 117, 91-98.	1.3	17
201	PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial. <i>Breast Cancer Research</i> , 2019, 21, 39.	2.2	17
202	Trajectories of alcohol consumption during life and the risk of developing breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 1168-1176.	2.9	17
203	Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer. <i>Oncotarget</i> , 2017, 8, 21930-21937.	0.8	17
204	Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 381-391.	0.7	16
205	Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 149-155.	1.1	16
206	Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET).. <i>Journal of Clinical Oncology</i> , 2015, 33, 508-508.	0.8	16
207	Effect of clavulanic acid and/or polymorphonuclear neutrophils on amoxicillin bactericidal activity against <i>Streptococcus pneumoniae</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1997, 16, 512-516.	1.3	15
208	Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). <i>Clinical and Translational Oncology</i> , 2009, 11, 363-375.	1.2	15
209	At the Bedside: Profiling and treating patients with CXCR4-expressing cancers. <i>Journal of Leukocyte Biology</i> , 2021, 109, 953-967.	1.5	15
210	Vinorelbine as a 96-Hour Continuous Infusion in Heavily Pretreated Patients with Metastatic Breast Cancer: A Cooperative Study by the GEICAM Group. <i>Clinical Breast Cancer</i> , 2003, 3, 399-404.	1.1	14
211	Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 129-139.	1.1	14
212	Efficacy and safety of immune checkpoint inhibitor immunotherapy in elderly cancer patients. <i>Clinical and Translational Oncology</i> , 2020, 22, 555-562.	1.2	14
213	GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID -19 Pandemic in Spain. <i>Oncologist</i> , 2020, 25, e1339-e1345.	1.9	14
214	Phase II study of ixabepilone in patients (pts) with taxane-resistant metastatic breast cancer (MBC): Final report. <i>Journal of Clinical Oncology</i> , 2006, 24, 10505-10505.	0.8	14
215	Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: A collaborative effort of the BIG-NCI NABCG.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1008-1008.	0.8	14
216	Docetaxel, Doxorubicin and Cyclophosphamide (the TAC regimen): An Effective Adjuvant Treatment for Operable Breast Cancer. <i>Women's Health</i> , 2006, 2, 527-537.	0.7	13

#	ARTICLE	IF	CITATIONS
217	Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists. <i>Clinical and Translational Oncology</i> , 2017, 19, 508-518.	1.2	13
218	Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis. <i>Oncologist</i> , 2017, 22, 1301-1308.	1.9	13
219	Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane. <i>Annals of Oncology</i> , 2018, 29, 1195-1202.	0.6	13
220	Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts. <i>Scientific Reports</i> , 2021, 11, 7064.	1.6	13
221	Technical Challenges for CTC Implementation in Breast Cancer. <i>Cancers</i> , 2021, 13, 4619.	1.7	13
222	Abstract PD3-06: Association of intrinsic subtypes with pathological complete response (pCR) in the KRISTINE neoadjuvant phase 3 clinical trial in HER2-positive early breast cancer (EBC). <i>Cancer Research</i> , 2018, 78, PD3-06-PD3-06.	0.4	13
223	Abstract GS1-07: Effects of capecitabine as part of neo-/adjuvant chemotherapy. A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients. <i>Cancer Research</i> , 2020, 80, GS1-07-GS1-07.	0.4	13
224	Abstract GS2-07: Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs)., 2020, , ,		13
225	Combining capecitabine and bevacizumab in metastatic breast cancer: A comprehensive review. <i>European Journal of Cancer</i> , 2012, 48, 482-491.	1.3	12
226	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021, 13, 4421.	1.7	12
227	Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline <i>BRCA1/2</i> -Mutated Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1383-1390.	3.2	12
228	Circulating tumour cells in locally advanced breast cancer. <i>Clinical and Translational Oncology</i> , 2009, 11, 544-547.	1.2	11
229	A randomized phase II non-comparative study of pemetrexed-carboplatin and gemcitabine-vinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients. <i>International Journal of Oncology</i> , 2013, 42, 1778-1785.	1.4	11
230	Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 181-189.	1.1	11
231	Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Tj ETQq1 1 0.784314 rgBT /Overlo	1.6	11
232	Serum Phospholipids Fatty Acids and Breast Cancer Risk by Pathological Subtype. <i>Nutrients</i> , 2020, 12, 3132.	1.7	11
233	Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2â€“) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALFESA-3. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS624-TPS624.	0.8	11
234	How we treat HR-positive, HER2-negative early breast cancer. <i>Future Oncology</i> , 2022, 18, 1003-1022.	1.1	11

#	ARTICLE	IF	CITATIONS
235	Clinical Experience With Pemetrexed in Breast Cancer. <i>Seminars in Oncology</i> , 2006, 33, 15-18.	0.8	10
236	Identification of genetic variants associated with capecitabine-induced handâ€“foot syndrome through integration of patient and cell line genomic analyses. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 231-237.	0.7	10
237	Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. <i>European Journal of Cancer</i> , 2015, 51, 685-696.	1.3	10
238	Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions. <i>Clinical and Translational Oncology</i> , 2017, 19, 341-356.	1.2	10
239	First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study. <i>Breast</i> , 2018, 38, 144-149.	0.9	10
240	Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy. <i>Clinical and Translational Oncology</i> , 2018, 20, 1548-1556.	1.2	10
241	Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations. <i>Drugs</i> , 2020, 80, 131-146.	4.9	10
242	Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile. <i>Current Cancer Drug Targets</i> , 2016, 16, 415-428.	0.8	10
243	A new era in the treatment of melanoma: from biology to clinical practice. <i>Clinical and Translational Oncology</i> , 2011, 13, 787-792.	1.2	9
244	Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study. <i>Scientific Reports</i> , 2020, 10, 7741.	1.6	9
245	A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS1107-TPS1107.	0.8	9
246	Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study. <i>European Journal of Cancer</i> , 2022, 168, 12-24.	1.3	9
247	Elementary, My Dear Watson. <i>Journal of Clinical Oncology</i> , 2007, 25, 1815-1816.	0.8	8
248	Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelial ovarian cancer patients. Long-term single institution experience and literature review. <i>Clinical and Translational Oncology</i> , 2011, 13, 121-132.	1.2	8
249	Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer. <i>Breast Care</i> , 2017, 12, 296-302.	0.8	8
250	Intratumoral BO-112, a double-stranded RNA (dsRNA), alone and in combination with systemic anti-PD-1 in solid tumors. <i>Annals of Oncology</i> , 2018, 29, viii732.	0.6	8
251	A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 303.	1.3	8
252	Association Between <i>ABC1</i> Genetic Variants and Persistent Chemotherapy-Induced Alopecia in Women With Breast Cancer. <i>JAMA Dermatology</i> , 2020, 156, 987.	2.0	8

#	ARTICLE	IF	CITATIONS
253	Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer. <i>Future Oncology</i> , 2020, 16, 2763-2778.	1.1	8
254	Phase III, randomized study of first-line trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs. trastuzumab + taxane (HT) treatment of HER2-positive MBC: Final overall survival (OS) and safety from MARIANNE.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1003-1003.	0.8	8
255	Dietary inflammatory index and breast cancer risk by menopausal status and histological subtype.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1521-1521.	0.8	8
256	Circulating tumoral cells lack circadian-rhythm in hospitalized metastatic breast cancer patients. <i>Clinical and Translational Oncology</i> , 2006, 8, 826-829.	1.2	7
257	Prognostic and predictive factors and genetic analysis of early breast cancer. <i>Clinical and Translational Oncology</i> , 2009, 11, 634-642.	1.2	7
258	Family History Record and Hereditary Cancer Risk Perception according to National Cancer Institute Criteria in a Spanish Medical Oncology Service: A Retrospective Study. <i>Oncology</i> , 2012, 82, 30-34.	0.9	7
259	Mouse p53-Deficient Cancer Models as Platforms for Obtaining Genomic Predictors of Human Cancer Clinical Outcomes. <i>PLoS ONE</i> , 2012, 7, e42494.	1.1	7
260	Endocrine therapy for hormone treatment-naïve advanced breast cancer. <i>Breast</i> , 2016, 28, 161-166.	0.9	7
261	Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer. <i>Future Oncology</i> , 2017, 13, 2137-2149.	1.1	7
262	Concordance of Genomic Variants in Matched Primary Breast Cancer, Metastatic Tumor, and Circulating Tumor DNA: The MIRROR Study. <i>JCO Precision Oncology</i> , 2019, 3, 1-16.	1.5	7
263	Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience. <i>Clinical and Translational Oncology</i> , 2020, 22, 717-724.	1.2	7
264	Abstract CTO61: A phase Ib study of alpelisib (BYL719) + everolimus ± exemestane in patients with advanced solid tumors or HR+/HER2-breast cancer. , 2016, , .		7
265	Abstract P6-07-09: Biomarker analysis from the neoadjuvant KRISTINE study in HER2-positive early breast cancer (EBC). <i>Cancer Research</i> , 2017, 77, P6-07-09-P6-07-09.	0.4	7
266	Abstract P3-09-19: Preliminary safety data of intrahepatic talimogene laherparepvec and intravenous atezolizumab in patients with triple negative breast cancer. , 2020, , .		7
267	A randomized, multicenter, double-blind phase III study of palbociclib (PD-0332991), an oral CDK 4/6 inhibitor, plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(â€“) breast cancer who have not received any prior systemic anticancer treatment for advanced disease.. <i>Journal of Clinical Oncology</i> . 2013. 31. TPS652-TPS652.	0.8	7
268	The association of early toxicity and outcomes for patients treated with abemaciclib.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1053-1053.	0.8	7
269	Interim results from the full population of the phase 3b CompleEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2â€“ advanced breast cancer (ABC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1041-1041.	0.8	7
270	Overview of preoperative radiochemotherapy in breast cancer: past or future?. <i>Clinical and Translational Oncology</i> , 2011, 13, 446-450.	1.2	6

#	ARTICLE	IF	CITATIONS
271	El c�ncer de mama. Arbor, 2015, 191, a234.	0.1	6
272	Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine�Induced Hand�Foot Syndrome. Clinical Pharmacology and Therapeutics, 2021, 109, 462-470.	2.3	6
273	Aggressiveness of end-of-life cancer care: what happens in clinical practice?. Supportive Care in Cancer, 2021, 29, 3121-3127.	1.0	6
274	A Cross-Sectional Comparison of Druggable Mutations in Primary Tumors, Metastatic Tissue, Circulating Tumor Cells, and Cell-Free Circulating DNA in Patients with Metastatic Breast Cancer: The MIRROR Study Protocol. JMIR Research Protocols, 2016, 5, e167.	0.5	6
275	Trans-generational radiation-induced chromosomal instability in the female enhances the action of chemical mutagens. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2008, 640, 16-26.	0.4	5
276	Unravelling the mystery of the TACT trial. Lancet, The, 2009, 373, 1662-1663.	6.3	5
277	Regional and seasonal influence in patient�s toxicity to adjuvant chemotherapy for early breast cancer. Breast Cancer Research and Treatment, 2011, 125, 273-278.	1.1	5
278	Phase 2 Study of Trabectedin in Patients With Hormone Receptor�Positive, HER-2�Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene. Clinical Breast Cancer, 2016, 16, 364-371.	1.1	5
279	Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit. Journal of Genetic Counseling, 2018, 27, 854-862.	0.9	5
280	Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study.. Journal of Clinical Oncology, 2019, 37, 500-500.	0.8	5
281	Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer. Clinical Cancer Research, 2022, 28, 1854-1862.	3.2	5
282	Methotrexate, Uracil and Tegafur, and Leucovorin Chemotherapy for Patients With Breast Cancer in Progression After High-Dose Chemotherapy With Peripheral Blood Progenitor Cell Transplant. American Journal of Clinical Oncology: Cancer Clinical Trials, 2000, 23, 617-621.	0.6	4
283	Breast cancer: complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma. Anti-Cancer Drugs, 2010, 21, S19-S22.	0.7	4
284	Understanding the value of antiangiogenic therapy in metastatic breast cancer. Current Opinion in Oncology, 2011, 23, S1.	1.1	4
285	Zooming in on the schedule of bone-modifying drugs. Lancet Oncology, The, 2013, 14, 575-576.	5.1	4
286	Maintenance therapy in breast cancer�many questions remain. Nature Reviews Clinical Oncology, 2013, 10, 370-372.	12.5	4
287	Exclusion Criteria vs Reality: Dual BRAF/MEK Inhibition and Radiotherapy in a Patient with Melanoma Metastatic to the Brain and ECOG 3. Tumori, 2016, 102, S54-S56.	0.6	4
288	Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. European Journal of Cancer, 2016, 56, 85-92.	1.3	4

#	ARTICLE	IF	CITATIONS
289	The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2 ⁻) breast cancer: When might multigene assays be of value?. <i>Breast</i> , 2017, 33, 191-199.	0.9	4
290	Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene. <i>Cancer Management and Research</i> , 2018, Volume 10, 4517-4522.	0.9	4
291	Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study. <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 814-818.	0.6	4
292	acelERA Breast Cancer (BC): Phase II study evaluating efficacy and safety of giredestrant (GDC-9545) versus physician's choice of endocrine monotherapy in patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) locally advanced or metastatic breast cancer (LA/mBC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS1100-TPS1100.	0.8	4
293	Abstract CT071: Talazoparib (TALA) in germlineBRCA1/2(gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): Final overall survival (OS) results from randomized Phase 3 EMBRACA trial. , 2020, , .		4
294	Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2 ⁻) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompleEment-1 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1056-1056.	0.8	4
295	EMBRACA: Efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline <i>BRCA</i> mutation.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1069-1069.	0.8	4
296	387&€...A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies. , 2020, , .		4
297	A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody&€“Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 625-634.	1.9	4
298	Moving forward with capecitabine: a glimpse of the future. <i>Oncologist</i> , 2002, 7 Suppl 6, 29-35.	1.9	4
299	Code of practice needed for samples donated by trial participants. <i>Lancet Oncology</i> , The, 2022, 23, e89-e90.	5.1	4
300	Impact of body mass index on treatment and outcomes in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 518-518.	0.8	4
301	Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials. <i>Onkologie</i> , 2013, 36, 363-367.	1.1	3
302	Phase III Study of Palbociclib in Combination with Exemestane Vs. Capecitabine, in Hormonal Receptor (Hr) Positive/Her2 Negative Metastatic Breast Cancer (Mbc) Patients with Resistance to Non-Steroidal Aromatase Inhibitors (Nsai): Pearl Study (Geicam/2013-02_Cecog/Bc.1.3.006). <i>Annals of Oncology</i> , 2014, 25, iv134.	0.6	3
303	Evaluation of a Heredofamilial Cancer Unit in Increasing Family History Collection and Genetic Counseling Referrals Among Spanish Oncologists at a University Hospital. <i>Journal of Genetic Counseling</i> , 2014, 23, 108-113.	0.9	3
304	Cyclin Kinase Inhibitors in Breast Cancer: From Bench to Bedside. <i>Current Breast Cancer Reports</i> , 2014, 6, 79-87.	0.5	3
305	S-1 versus taxanes for HER2-negative metastatic breast cancer. <i>Lancet Oncology</i> , The, 2016, 17, 11-12.	5.1	3
306	EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. <i>Annals of Oncology</i> , 2018, 29, viii96.	0.6	3

#	ARTICLE	IF	CITATIONS
307	Subcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysis. <i>Annals of Oncology</i> , 2018, 29, viii103.	0.6	3
308	Pharmacogenetic variants and response to neoadjuvant single-agent doxorubicin or docetaxel. <i>Pharmacogenetics and Genomics</i> , 2018, 28, 245-250.	0.7	3
309	Etiology and Prognosis of Pneumonia in Patients with Solid Tumors: A Prospective Cohort of Hospitalized Cases. <i>Oncologist</i> , 2020, 25, e861-e869.	1.9	3
310	Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 517-517.	0.8	3
311	Abstract CT092: A phase II study of neoadjuvant abemaciclib (LY2835219) in postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer (neoMONARCH). , 2016, , .		3
312	Abstract 785: Genomic markers of response to monotherapy abemaciclib in the nextMONARCH 1 study. , 2020, , .		3
313	Nabrax: Neoadjuvant therapy of breast cancer with weekly single-agent nab-paclitaxel Final efficacy and biomarkers analysis of GEICAM 2011-02 trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1051-1051.	0.8	3
314	First-in-human clinical trial with intratumoral BO-112 in solid malignancies: A novel immunotherapy based in double-stranded RNA (dsRNA).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3082-3082.	0.8	3
315	Timing of initiation of neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ hormone receptor (HR)-negative breast cancer: Exploratory analyses from the phase III ExteNET trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 549-549.	0.8	3
316	IMpassion132: A double-blind randomized phase 3 trial evaluating chemotherapy (CT) ± atezolizumab (atezo) for early progressing locally advanced/metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS1115-TPS1115.	0.8	3
317	Chemotherapy Plus Bevacizumab as Neoadjuvant or Conversion Treatment in Patients with Colorectal Liver Metastases. <i>Anticancer Research</i> , 2018, 38, 3069-3077.	0.5	3
318	Abstract CT099: The benefit of abemaciclib in prognostic subgroups: An update to the pooled analysis of MONARCH 2 and 3. , 2018, , .		3
319	Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from MONALEESA-3. , 2018, 78, .		3
320	Type does matter. Use VIRGIN olive oil as your preferred fat to reduce your risk of breast cancer: case-control EpiGEICAM study. <i>European Journal of Clinical Nutrition</i> , 2022, 76, 1343-1346.	1.3	3
321	Proposal for the Creation of a National Strategy for Precision Medicine in Cancer: a position statement of SEOM, SEAP and SEFH. <i>Farmacia Hospitalaria</i> , 2017, 41, 688-691.	0.6	3
322	Time-to-progression in breast cancer: A stratification model for clinical trials. <i>Breast</i> , 2008, 17, 239-244.	0.9	2
323	A Multicenter, Single-Arm Phase II Study of Pemetrexed Plus Doxorubicin Administered Every 21 Days in Patients With Advanced Breast Cancer. <i>Clinical Breast Cancer</i> , 2009, 9, 155-160.	1.1	2
324	Current controversies in the management of breast cancer. <i>Clinical and Translational Oncology</i> , 2010, 12, 278-286.	1.2	2

#	ARTICLE	IF	CITATIONS
325	Reply to Y. Yamamoto et al. Journal of Clinical Oncology, 2013, 31, 2517-2518.	0.8	2
326	Adoption of Multi-Gene Assays in HR +, HER2+ Breast Cancer (BC) Patients in Europe: Results of the Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) Survey. Annals of Oncology, 2014, 25, i5.	0.6	2
327	SEOM Guidelines 2015: a new era in the collaboration with the Spanish Cancer Research Cooperative Groups. Clinical and Translational Oncology, 2015, 17, 937-938.	1.2	2
328	RE: Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM Trial. Journal of the National Cancer Institute, 2017, 109, 1.	3.0	2
329	Biosimilars. ESMO Open, 2018, 3, e000321.	2.0	2
330	EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology, 2018, 29, viii96-viii97.	0.6	2
331	The LILAC trial and the blooming of anticancer biosimilars. Lancet Oncology, The, 2018, 19, 861-863.	5.1	2
332	Neratinib for the treatment of early-stage, hormone receptor-positive, HER2-overexpressed breast cancer. Future Oncology, 2020, 16, 1165-1177.	1.1	2
333	Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population. Clinical and Translational Oncology, 2020, 22, 1857-1866.	1.2	2
334	Prognostic value of molecular biomarkers in patients with metastatic colorectal cancer: a real-world study. Clinical and Translational Oncology, 2021, 23, 122-129.	1.2	2
335	Iterative Variable Selection for High-Dimensional Data: Prediction of Pathological Response in Triple-Negative Breast Cancer. Mathematics, 2021, 9, 222.	1.1	2
336	How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer. Oncology and Therapy, 2021, 9, 297-309.	1.0	2
337	DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach. Journal of Personalized Medicine, 2021, 11, 792.	1.1	2
338	Abstract OT1-1-12: A phase 3, open-label, randomized, parallel, 2-arm multi-center study of the oral PARP inhibitor BMN 673 versus physician's choice in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA study). Cancer Research, 2015, 75, OT1-1-12-OT1-1-12.	0.4	2
339	Abstract P5-19-02: Everolimus in combination with exemestane in hormone receptor-positive locally advanced or metastatic breast cancer (BC) patients progressing on prior non-steroidal AI (NSAIs): Ballet study (CRAD001YIC04)., 2015, , .		2
340	Abstract P6-08-10: Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in women with estrogen receptor-positive, HER2-negative, node-negative breast cancer: A GEICAM study. , 2015, , .		2
341	Abstract OT1-08-06: International, phase 3 trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS) international, phase 3 trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS)., 2020,		2
342	Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal-related events (SREs) in patients with metastatic bone disease: Subgroup analyses by baseline characteristics.. Journal of Clinical Oncology, 2014, 32, 9501-9501.	0.8	2

#	ARTICLE	IF	CITATIONS
343	Phase I study of the combination of balixafortide (CXCR4 inhibitor) and eribulin in HER2-negative metastatic breast cancer (MBC) patients (pts).. Journal of Clinical Oncology, 2017, 35, 2555-2555.	0.8	2
344	Balixafortide (a CXCR4 antagonist) + eribulin in HER2-negative metastatic breast cancer (MBC): Survival outcomes of the phase I trial.. Journal of Clinical Oncology, 2019, 37, 2606-2606.	0.8	2
345	Incidence of venous thromboembolic disease (VTE) in a cohort of patients with colorectal cancer (CRC) according to KRAS, NRAS and BRAF status.. Journal of Clinical Oncology, 2019, 37, e15136-e15136.	0.8	2
346	Metastatic melanoma with spontaneous regression, psoriasis and HLA-Cw6: case report and a hypothesis to explore. Tumori, 2014, 100, 144e-7e.	0.6	2
347	P1-06-04: PAM50 Proliferation Index Predicts Response to Weekly Adjuvant Paclitaxel in Node-Positive Operable Breast Cancer.. , 2011, , .		2
348	Abstract CT072: Exploration of impact of tumorBRCAzygosity and genomic loss-of-heterozygosity (gLOH) on efficacy in Phase 3 EMBRACA study of talazoparib in patients (pts) with HER2-negative (HER2â”) advanced breast cancer (ABC) and a germlineBRCA1/2(gBRCA1/2) mutation. , 2020, , .		2
349	Abstract OT2-07-01: A phase 2 study of futibatinib (TAS-120) in metastatic breast cancers harboring fibroblast growth factor receptor (<i>FGFR</i>) amplifications (FOENIX-MBC2). Cancer Research, 2020, 80, OT2-07-01-OT2-07-01.	0.4	2
350	HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping. Cancers, 2022, 14, 512.	1.7	2
351	The importance of physical exercise in cardiovascular fitness in breast cancer survivors. A cross-sectional study: women in Motion 2.0. Supportive Care in Cancer, 2022, 30, 6745-6754.	1.0	2
352	Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress).. Journal of Clinical Oncology, 2022, 40, TPS1108-TPS1108.	0.8	2
353	Life-threatening Complications From Doxorubicin-Docetaxel Chemotherapy for Breast Cancer. JAMA - Journal of the American Medical Association, 2005, 294, 2166.	3.8	1
354	Molecular haplotyping of tandem single nucleotide polymorphisms by allele-specific PCR. Analytical Biochemistry, 2007, 364, 153-158.	1.1	1
355	Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007. Clinical and Translational Oncology, 2008, 10, 552-559.	1.2	1
356	Corrigendum to â€œDocetaxel-related side effects and their managementâ€•[European Journal of Oncology Nursing 12 (2008) 253â€“268]. European Journal of Oncology Nursing, 2008, 12, 479.	0.9	1
357	Reply to R.S. Mehta et al. Journal of Clinical Oncology, 2009, 27, 3068-3069.	0.8	1
358	3540 POSTER Perception of Hereditary Cancer Risk in a Medical Oncology Service: a Retrospective Study. European Journal of Cancer, 2011, 47, S258.	1.3	1
359	AOSOP6 Results from the 2-year open-label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer, 2012, 48, S3.	1.3	1
360	Denosumab Versus Placebo as Adjuvant Treatment for Women With Early-Stage Breast Cancer at High Risk of Disease Recurrence (D-CARE): An in Progress, Phase 3 Clinical Trial. Annals of Oncology, 2012, 23, ix115.	0.6	1

#	ARTICLE	IF	CITATIONS
361	Efficacy of Fulvestrant According to Duration and Type of Adjuvant Endocrine Treatment, in Metastatic Breast Cancer Patients Enrolled in the Confirm Trial. <i>Annals of Oncology</i> , 2014, 25, i8.	0.6	1
362	Vinflunine (Vfl) Plus Capecitabine (Cape) for Advanced Breast Cancer (Abc) Previously Treated with or Resistant to Anthracycline and Resistant to Taxane : a Phase 3 Study Versus Capecitabine. <i>Annals of Oncology</i> , 2014, 25, iv119.	0.6	1
363	Optimizing Adjuvant Taxanes in Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2334-2336.	0.8	1
364	SEOM guidelines 2016: an update. <i>Clinical and Translational Oncology</i> , 2016, 18, 1161-1162.	1.2	1
365	Tuning up adjuvant endocrine therapy: the TEAM trial. <i>Lancet Oncology</i> , The, 2017, 18, 1145-1146.	5.1	1
366	Balixafortide (a CXCR4 antagonist) plus eribulin in HER2-negative metastatic breast cancer (MBC): A Phase I open-label trial. <i>European Journal of Cancer</i> , 2018, 92, S117-S118.	1.3	1
367	Venous thromboembolism incidence in cancer patients with germline BRCA mutations. <i>Clinical and Translational Oncology</i> , 2021, , 1.	1.2	1
368	Abstract OT1-1-06: A phase I study of LDE225 in combination with docetaxel in patients with triple negative (TN) advanced breast cancer (ABC): GEICAM/2012-12 (EDALINE study). , 2015, , .		1
369	Randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer (BC) comparing FAC with FAC followed by weekly paclitaxel: First efficacy analysis of the GEICAM/2003-02 trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1001-1001.	0.8	1
370	A phase II trial of trabectedin (T) in patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to xeroderma pigmentosum gene (XPG) expression.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS652-TPS652.	0.8	1
371	Vinflunine plus capecitabine for advanced breast cancer previously treated with or resistant to anthracycline and resistant to taxane: A phase III study versus capecitabine.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1013-1013.	0.8	1
372	Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 117-117.	0.8	1
373	Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1071-1071.	0.8	1
374	Incidence and prediction of venous thromboembolism (VTE) in ambulatory patients (pts) with pancreas cancer receiving chemotherapy.. <i>Journal of Clinical Oncology</i> , 2012, 30, 368-368.	0.8	1
375	Pharmacogenetic biomarkers for predisposition to toxicity to adjuvant FOLFOX/XELOX in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 390-390.	0.8	1
376	Final results of a phase II trial of trabectedin (T) in patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to xeroderma pigmentosum gene (XPG) expression.. <i>Journal of Clinical Oncology</i> , 2013, 31, 547-547.	0.8	1
377	Subtype analysis from the GEICAM/2003-02 study: High-risk, node-negative breast cancer patients treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11107-11107.	0.8	1
378	Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 547-547.	0.8	1

#	ARTICLE	IF	CITATIONS
379	Outcomes of single versus double hormone receptor positive breast cancer.. Journal of Clinical Oncology, 2016, 34, 569-569.	0.8	1
380	HER2 gene amplification testing by fluorescence in situ hybridization (FISH): Comparison of the ASCO-CAP guidelines with FISH scores used for enrollment in breast cancer international research group (BCIRG) clinical trials.. Journal of Clinical Oncology, 2016, 34, 515-515.	0.8	1
381	Prognostic and predictive factors in metastatic colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 690-690.	0.8	1
382	Abstract CT040: MONARCH 3: Abemaciclib as initial therapy for patients with HR+, HER2- advanced breast cancer - Results from the preplanned final PFS analysis. , 2018, , .		1
383	Abstract PD13-01: Balixafortide (a CXCR4 antagonist)+eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer: An international, randomized, phase 3 trial (FORTRESS). Cancer Research, 2022, 82, PD13-01-PD13-01.	0.4	1
384	Cancer therapy with unloaded monocyte-derived dendritic cells in patients with inoperable pancreatic and gall bladder cancer. Journal of Clinical Oncology, 2004, 22, 2569-2569.	0.8	1
385	Introduction. Seminars in Oncology, 2006, 33, 1.	0.8	0
386	PMS66 WILLINGNESS TO PAY VS. QUALITY ADJUSTEDWAGES AS ALTERNATIVE WAYS TO MEASURE THE BURDEN OF DISEASE IN SPAIN: AN APPLICATION TO BALLOON KYPHOPLASTY. Value in Health, 2008, 11, A557-A558.	0.1	0
387	Reply to L.C. Panasci. Journal of Clinical Oncology, 2009, 27, e112-e113.	0.8	0
388	Retrospective subset analyses in early breast cancer revisited. Lancet Oncology, The, 2009, 10, 1136-1137.	5.1	0
389	Application of new methodology to allow comparison of duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial. Breast, 2011, 20, S45.	0.9	0
390	Lower Breast Cancer Risk among Women Following Lifestyle Recommendations: A Case-Control Study in Spain.. International Journal of Epidemiology, 2015, 44, i136-i136.	0.9	0
391	P105 The MAGIC survey in HR+, HER2â” breast cancer (BC): when might multigene assays be of value?. Breast, 2015, 24, S61.	0.9	0
392	Evaluation of breast cancer patients with genetic risk: Before and after a multidisciplinary heredofamiliar cancer unit implementation. Annals of Oncology, 2016, 27, vi465.	0.6	0
393	Final Survival Analysis of ROSE/TRIO-012. Journal of Clinical Oncology, 2016, 34, 3714-3715.	0.8	0
394	ACE and CXCL10 as predictive biomarkers in the LEA study. Annals of Oncology, 2016, 27, vi41.	0.6	0
395	Denosumab for the prevention of symptomatic skeletal events (SSEs) in patients with bone-metastatic breast cancer: A comparison with skeletal-related events (SREs). Annals of Oncology, 2016, 27, vi507.	0.6	0
396	Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM â€œEl Âłamo IIIâ€• retrospective study. PLoS ONE, 2017, 12, e0184181.	1.1	0

#	ARTICLE	IF	CITATIONS
397	PCN20 - CONTRIBUTION OF TRASTUZUMAB TO THE PROGNOSTIC IMPROVEMENT OF HER2-POSITIVE EARLY BREAST CANCER IN SPAIN. <i>Value in Health</i> , 2018, 21, S18.	0.1	0
398	Balixafortide (a novel CXCR4 inhibitor) and eribulin in HER2-neg metastatic breast cancer (MBC) patients (pts): A phase I trial. <i>Annals of Oncology</i> , 2018, 29, viii91-viii92.	0.6	0
399	NOLUS: a predictive model to identify Basal-like and HER2-enriched intrinsic subtypes based on estrogen receptor (ER), progesterone receptor (PR) and Ki67 immunohistochemistry (IHC) in hormone receptor-positive/HER2-negative (HR+/HER2 ⁻) breast cancer (BC). <i>European Journal of Cancer</i> , 2018, 92, S138.	1.3	0
400	Efficacy of neratinib in hormone receptor-positive (HR+) patients who initiated treatment within 1 year of completing trastuzumab-based adjuvant therapy in HER2+ early-stage breast cancer (BC): subgroup analyses from the phase III ExteNET trial. <i>Breast</i> , 2019, 44, S18-S19.	0.9	0
401	RIBOCICLIB (RIB) + LETROZOLE (LET) IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL RECEPTOR-2 ⁻ NEGATIVE (HER2 ⁻) ADVANCED BREAST CANCER (ABC) BY DOSE INTENSITY: PRELIMINARY SUBGROUP RESULTS FROM THE PHASE 3B COMPLEEMENT-1 TRIAL. <i>Breast</i> , 2019, 48, S46.	0.9	0
402	A PLAIN-LANGUAGE SUMMARY OF THE COMPLEEMENT-1 STUDY: RIBOCICLIB AND LETROZOLE AS FIRST LINE THERAPY IN A STUDY OF 3,246 PEOPLE WITH ADVANCED BREAST CANCER. <i>Breast</i> , 2019, 48, S49-S50.	0.9	0
403	Situation, challenges, and SEOM recommendations for the future of undergraduate education in Oncology in Spain. <i>Clinical and Translational Oncology</i> , 2020, 22, 1049-1058.	1.2	0
404	Reply to Y. Usui et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 2113-2114.	0.8	0
405	Nephrotic syndrome in a 60-year-old man. <i>Journal of Clinical Pathology</i> , 2020, 73, e3-e3.	1.0	0
406	Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice. <i>Supportive Care in Cancer</i> , 2021, 29, 4673-4681.	1.0	0
407	Reply to K. Hashimoto and A. Shimomura. <i>Journal of Clinical Oncology</i> , 2021, 39, 1507-1508.	0.8	0
408	Neutropenic fever and neoadjuvant intraperitoneal and systemic chemotherapy (DCF-like) in gastric cancer with peritoneal dissemination.. <i>Journal of Clinical Oncology</i> , 2012, 30, 144-144.	0.8	0
409	Family history record and hereditary cancer risk perception after the creation of a hereditary cancer unit in a Spanish hospital.. <i>Journal of Clinical Oncology</i> , 2012, 30, e12003-e12003.	0.8	0
410	Prognostic value of KRAS in terms of efficacy and safety of bevacizumab as neoadjuvant or conversion treatment in patients with colorectal liver metastasis.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14058-e14058.	0.8	0
411	Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE): An international, randomized, double-blind, placebo-controlled phase III clinical trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS670-TPS670.	0.8	0
412	Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, placebo-controlled, randomized, double-blind phase III clinical trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS662-TPS662.	0.8	0
413	Breast cancer risk among women following lifestyle recommendations: A case-control study in Spain.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1602-1602.	0.8	0
414	Abstract P5-15-08: Exercise intervention to run away from breast cancer treatment side effects: An integrative approach. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
415	Abstract P2-13-17: Impact on survival of primary tumor resection in women with de novo metastatic breast cancer. The GEICAM Alamo III breast cancer registry (1990-2001). , 2015, , .		0
416	Abstract P6-08-06: The multidisciplinary application of genomics in clinical practice (MAGIC) survey: Identification of early stage hormone receptor-positive (HR+), HER2-“ breast cancer (BC) patients for whom multigene assays may be valuable. , 2015, , .		0
417	Bevacizumab plus Letrozol (LEA clinical trial phase III). Using hypertension for finding biomarkers of efficacy.. Journal of Clinical Oncology, 2015, 33, 2524-2524.	0.8	0
418	Implication of MODEL of financing clinical research in breast cancer during the past two decades.. Journal of Clinical Oncology, 2016, 34, e14046-e14046.	0.8	0
419	Patient-reported outcomes (PROs) from MARIANNE: A phase III study of trastuzumab emtansine (T-DM1) +/- pertuzumab (P) vs trastuzumab + taxane (HT) for HER2-positive advanced breast cancer.. Journal of Clinical Oncology, 2016, 34, 593-593.	0.8	0
420	The implementation of a multidisciplinary hereditary cancer unit to increase the referral and preventive surgeries of breast cancer patients with genetic risk in a university hospital.. Journal of Clinical Oncology, 2016, 34, e13031-e13031.	0.8	0
421	Evaluating the addition of bevacizumab (Bev) to endocrine therapy as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.. Journal of Clinical Oncology, 2017, 35, 1012-1012.	0.8	0
422	A phase 2 study of investigational TORC1/2 inhibitor TAK-228 with fulvestrant in women with ER+/HER2-“advanced or metastatic breast cancer (mBC) that has progressed during or after aromatase inhibitor (AI) therapy.. Journal of Clinical Oncology, 2017, 35, TPS1118-TPS1118.	0.8	0
423	Abstract 3607: Quantitative dimensions of the PAM50 in breast tumors are prognostic and predict paclitaxel response. , 2018, , .		0
424	Simulation modeling approaches to answer clinically relevant questions in breast cancer low-risk populations. Annals of Translational Medicine, 2018, 6, S80-S80.	0.7	0
425	Retrospective analysis of clinical characteristics of mCRC patients receiving three or more lines of chemotherapy.. Journal of Clinical Oncology, 2019, 37, 682-682.	0.8	0
426	Phase Ib study of talimogene laherparepvec (T-VEC) injection into liver metastases (LMs) in combination with intravenous (IV) atezolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or colorectal cancer (CRC).. Journal of Clinical Oncology, 2019, 37, TPS725-TPS725.	0.8	0
427	Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval. Oncotarget, 2019, 10, 4321-4332.	0.8	0
428	Abstract PD5-11: Association of immune gene expression with outcome in the MARIANNE phase 3 clinical trial in HER2-positive metastatic breast cancer (MBC). , 2020, , .		0
429	Abstract P1-18-05: Subcutaneous trastuzumab and hyaluronidase-oysk with intravenous pertuzumab and docetaxel in HER2-positive advanced breast cancer: Final analysis of the phase IIIb, multicenter, open-label, single-arm MetaPHER study. , 2020, , .		0
430	Abstract OT2-02-02: MONARCH E: A phase 3 study of standard adjuvant endocrine therapy with or without abemaciclib in patients with high risk, node positive, hormone-receptor positive, human epidermal growth factor receptor 2-negative early-stage breast cancer. , 2020, , .		0
431	Abstract P1-10-09: The MHCII immune activation assay is prognostic for disease free survival in basal-like TNBC breast cancer patients in the GEICAM/9906 clinical trial. , 2020, , .		0
432	Abstract P1-19-09: Updated subgroup tumor response of abemaciclib plus aromatase inhibitor for hormone receptor positive (HR+), HER2 negative advanced breast cancer (MONARCH 3). , 2020, , .		0

#	ARTICLE	IF	CITATIONS
433	Abstract P1-19-21: Ribociclib + letrozole in patients with HR+, HER2 ⁺ advanced breast cancer: Safety analysis of the phase 3b CompleEment-1 trial. , 2020, , .		0
434	Abstract P1-19-29: An integrated safety analysis of talazoparib monotherapy from five clinical trials (phase 1-3) in advanced cancers. , 2020, , .		0
435	Prognosis and correlation with Ca19.9 of circulating tumor cells (CTCs) in locally advanced and metastatic pancreatic cancer.. Journal of Clinical Oncology, 2022, 40, 586-586.	0.8	0
436	Effect of oxodipine and nifedipine on guinea-pig ileum. General Pharmacology, 1988, 19, 771-4.	0.7	0
437	Abstract GS1-07: Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial. Cancer Research, 2022, 82, GS1-07-GS1-07.	0.4	0